JohnSPollackMD

Retinal Disease

Partner, Illinois Retina Associates; Asst. Prof. Ophthalmology, Rush University Medical Center; Chief Medical Officer, jCyte

Join to view full profile

Dr. Pollack is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pollack's full profile

Already have an account?

Office
12 Salt Creek Lane, Suite 110
Hinsdale, IL 60521

Education & Training

Medical College of WisconsinFellowship, 1995 - 1997
Washington University/B-JH/SLCH ConsortiumResidency, Ophthalmology, 1992 - 1995
Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 1991 - 1992
Georgetown University School of MedicineClass of 1991

Certifications & Licensure

IL State Medical License 1997 - 2026
MO State Medical License 1992 - 2015
WI State Medical License 1995 - 2009
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Retina Hall of Fame – Charter Inductee Retina Hall of Fame, 2017
OSN Retina 150 Innovators in Medical and Surgical Retina OSN Retina, 2015
American Academy of Ophthalmology "Achievement Award" American Academy of Ophthalmology, 2010
American Society of Retina Specialists "Senior Honor Award" American Society of Retina Specialists, 2001
Join now to see all

Clinical Trials

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) Start of enrollment: 2006 Jun 01
Completed
Phase 2
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial Start of enrollment: 2008 Feb 01
Completed
Phase 3
Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections Start of enrollment: 2009 Oct 01
Completed
Phase 3
Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study Start of enrollment: 2010 Feb 01
Completed
Phase 2
Phase II Combination Steroid and Anti-VEGF for Persistent DME Start of enrollment: 2014 Feb 01
Completed
Phase 2
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Start of enrollment: 2014 Sep 01
Completed
Phase 3
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration Start of enrollment: 2015 Sep 28
Completed
Phase 2
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration Start of enrollment: 2018 Sep 12
Completed
Phase 3
Extension Study for the Port Delivery System With Ranibizumab (Portal) Start of enrollment: 2018 Sep 20
Recruiting
Phase 3
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab Start of enrollment: 2019 Sep 30
Active, not recruiting
Phase 3
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy Start of enrollment: 2019 Nov 15
Completed
Phase 3
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm Start of enrollment: 2020 Aug 10
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

15 citations
Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outc...
Thomas A Ciulla, Rehan M Hussain, Donna Taraborelli, John S Pollack, David F Williams
Ophthalmology. Retina. 2022-09-01
97 citations
Real-world Outcomes of Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States
Thomas A. Ciulla, Peter Bracha, John S. Pollack, David F. Williams
Ophthalmology. Retina. 2018-07-29
80 citations
Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes
Thomas A. Ciulla, John S. Pollack, David F. Williams
The British Journal of Ophthalmology. 2021-02-01

Press Mentions

Big Data, Analytics, and AI in Retina PracticeNovember 1st, 2019
REGENXBIO Reports Continued Progress Across Programs in Year-End 2018 Corporate UpdateJanuary 3rd, 2019
Tributes to a Legend in Retina: Kirk Packo, MD, FACSOctober 3rd, 2023